Insider Buys
This tool is in beta, validation in progress.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Score components and checks ✓/✗ are not accurate for every transaction yet.
Risk Factors Update Summary
- The company reported a net loss of approximately $13 million in Fiscal 2024, up from $11.5 million in Fiscal 2023. This change might indicate worsening financial performance.
- The company owns land in Nagpur valued at approximately $720 thousand and other assets totaling about $500 thousand, which are non-core to its pharmaceutical focus.
- As of June 18, 2024, executive officers and large shareholders owned 31.48% of common stock, limiting influence on corporate matters and potentially depressing stock price.
- The company may face significant risks in its artificial intelligence initiatives, impacting business reputation and financial results due to evolving regulatory scrutiny and legal liabilities.
- The company’s cash and cash equivalents decreased from $3.2 million to $1.4 million, indicating potential liquidity challenges affecting operational stability.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1326205&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.